Differences between plasma and cerebrospinal fluid glial fibrillary acidic protein levels across the Alzheimer disease continuum
…, J Dumurgier, J Stevenson, N Rahmouni… - JAMA …, 2021 - jamanetwork.com
Importance Glial fibrillary acidic protein (GFAP) is a marker of reactive astrogliosis that
increases in the cerebrospinal fluid (CSF) and blood of individuals with Alzheimer disease (AD). …
increases in the cerebrospinal fluid (CSF) and blood of individuals with Alzheimer disease (AD). …
[HTML][HTML] Astrocyte reactivity influences amyloid-β effects on tau pathology in preclinical Alzheimer's disease
…, J Therriault, S Servaes, J Stevenson, N Rahmouni… - Nature medicine, 2023 - nature.com
An unresolved question for the understanding of Alzheimer’s disease (AD) pathophysiology
is why a significant percentage of amyloid-β (Aβ)-positive cognitively unimpaired (CU) …
is why a significant percentage of amyloid-β (Aβ)-positive cognitively unimpaired (CU) …
Association of phosphorylated tau biomarkers with amyloid positron emission tomography vs tau positron emission tomography
…, G Bezgin, J Stevenson, N Rahmouni… - JAMA …, 2023 - jamanetwork.com
Importance The recent proliferation of phosphorylated tau (p-tau) biomarkers has raised
questions about their preferential association with the hallmark pathologies of Alzheimer …
questions about their preferential association with the hallmark pathologies of Alzheimer …
APOEε4 associates with microglial activation independently of Aβ plaques and tau tangles
…, G Bezgin, MS Kang, J Stevenson, N Rahmouni… - Science …, 2023 - science.org
Animal studies suggest that the apolipoprotein E ε4 (APOEε4) allele is a culprit of early
microglial activation in Alzheimer’s disease (AD). Here, we tested the association between …
microglial activation in Alzheimer’s disease (AD). Here, we tested the association between …
[HTML][HTML] A two-step workflow based on plasma p-tau217 to screen for amyloid β positivity with further confirmatory testing only in uncertain cases
Cost-effective strategies for identifying amyloid-β (Aβ) positivity in patients with cognitive
impairment are urgently needed with recent approvals of anti-Aβ immunotherapies for Alzheimer…
impairment are urgently needed with recent approvals of anti-Aβ immunotherapies for Alzheimer…
[HTML][HTML] Astrocyte biomarker signatures of amyloid-β and tau pathologies in Alzheimer's disease
…, G Bezgin, MS Kang, J Stevenson, N Rahmouni… - Molecular …, 2022 - nature.com
Astrocytes can adopt multiple molecular phenotypes in the brain of Alzheimer’s disease (AD)
patients. Here, we studied the associations of cerebrospinal fluid (CSF) glial fibrillary acidic …
patients. Here, we studied the associations of cerebrospinal fluid (CSF) glial fibrillary acidic …
[HTML][HTML] Comparing tau status determined via plasma pTau181, pTau231 and [18F] MK6240 tau-PET
…, DL Tudorascu, J Stevenson, N Rahmouni… - …, 2022 - thelancet.com
Background Tau in Alzheimer's disease (AD) is assessed via cerebrospinal fluid (CSF) and
Positron emission tomography (PET). Novel methods to detect phosphorylated tau (pTau) in …
Positron emission tomography (PET). Novel methods to detect phosphorylated tau (pTau) in …
[HTML][HTML] Mass spectrometric simultaneous quantification of tau species in plasma shows differential associations with amyloid and tau pathologies
…, J Stevenson, J Nilsson, M Sauer, N Rahmouni… - Nature Aging, 2023 - nature.com
Blood phosphorylated tau (p-tau) biomarkers, at differing sites, demonstrate high accuracy
to detect Alzheimerʼs disease (AD). However, knowledge on the optimal marker for disease …
to detect Alzheimerʼs disease (AD). However, knowledge on the optimal marker for disease …
[HTML][HTML] CSF p-tau205: a biomarker of tau pathology in Alzheimer's disease
Post-mortem staging of Alzheimer’s disease (AD) neurofibrillary pathology is commonly
performed by immunohistochemistry using AT8 antibody for phosphorylated tau (p-tau) at …
performed by immunohistochemistry using AT8 antibody for phosphorylated tau (p-tau) at …
Equivalence of plasma p‐tau217 with cerebrospinal fluid in the diagnosis of Alzheimer's disease
…, S Servaes, C Tissot, N Rahmouni… - Alzheimer's & …, 2023 - Wiley Online Library
INTRODUCTION Plasma biomarkers are promising tools for Alzheimer's disease (AD)
diagnosis, but comparisons with more established biomarkers are needed. METHODS We …
diagnosis, but comparisons with more established biomarkers are needed. METHODS We …
